2025-06-10-花旗集团-再鼎医药（ZLAB）_再鼎医药（ZLAB.O）2025年第一季度模型更新_12页_540kb

Zai Lab (ZLAB.O) - Citi Research Model Update Summary

Target Price Update

• Action: Zai Lab Buy/High Risk rating; target price lowered from $71 to $66.
• Justification: Adjustments to 1Q25 model, including reflecting year-end 2024 share count and revenue slightly lower than prior first-half 2024 weighted-average.
• Catalyst: Upside potential with expiration on August 7, 2025, linked to Vyvgart performance.

Key Forecasts & Financials

• EPS: 2025E shows improving margins, moving to positive EBITDA in 4Q25 with projected $1.22 billion revenue for 2025.
• Non-GAAP Profitability: Expected by YE25, aligning with management targets.
• Valuation Metrics:
  • Target Share Price Return: 74.3%.
  • Market Cap: ~$4.2 billion.
  • P/E (2025E): -31.1x; PB: 4.8x.

Company Description

• Biopharmaceutical company commercializing therapies in China, focusing on in-licensing foreign drugs and building an internal pipeline (e.g., DLL3).
• Seven commercial products in Greater China (Zejula, Vyvgart, etc.).

Investment Strategy

• Rating: Buy/High Risk, backed by strategy involving product launches and revenue expansion via pipeline drugs (e.g., bemarituzumab, KarXT).
• Revenue targets: $560–590M for 2025.

Catalysts & Risks

• Upside Catalysts: Vyvgart, bemarituzumab (70% PoS), KarXT (90% PoS).
• Risks: High sensitivity to China regulatory changes; potential underperformance of key products; clinical trial failures.

Summary Insights

• Citigroup expects revenue acceleration and profitability feasibility, though the valuation reflects high risk factors inherent in the company's operating environment.